SCHEMBL9890680

SCHEMBL9890680

Cc1ccc(CC(=O)O)c(-c2cccc(F)c2)c1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SRC P12931 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.46
KDM4E B2RXH2 1/20 0.46
PTGS1 P23219 2/20 0.44
PTGER2 P43116 3/20 0.44
PTGS2 P35354 3/20 0.44
PTGDR2 Q9Y5Y4 3/20 0.44
TBXA2R P21731 1/20 0.44
PTGDR Q13258 1/20 0.44
PPARG P37231 3/20 0.43
ABCB11 O95342 1/20 0.43
NR1I3 Q14994 1/20 0.43
CHRM3 P20309 3/20 0.43
HSP90AA1 P07900 1/20 0.42
MAPT P10636 1/20 0.42
HPGD P15428 1/20 0.42
ALOX15 P16050 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9890677 0.89 PTGS2 (0.47) SRCSMN1; SMN2KDM4EPTGS1PTGER2
SCHEMBL9890666 0.88 PTGDR2 (0.50) SMN1; SMN2KDM4EPTGS1PTGER2PTGS2
SCHEMBL9890788 0.87 ICMT (0.50) SMN1; SMN2PTGER2CHRM3HSP90AA1MAPT
SCHEMBL9890649 0.85 PTGS1 (0.59) SRCSMN1; SMN2PTGS1PTGER2PTGS2
SCHEMBL9105295 0.82 PTGER1 (0.57) SMN1; SMN2KDM4EPTGS1PTGER2PTGS2
SCHEMBL9890679 0.81 KDM4E (0.49) SMN1; SMN2KDM4EPTGS1PTGER2PTGDR2
SCHEMBL9892663 0.81 GCGR (0.49) SMN1; SMN2KDM4EPTGDR2TBXA2RPTGDR
SCHEMBL15832033 0.79 TAAR1 (0.49) SMN1; SMN2KDM4ECHRM3HSP90AA1MAPT
SCHEMBL9890671 0.79 PTGDR2 (0.50) SMN1; SMN2KDM4EPTGS1PTGER2PTGDR2
SCHEMBL9890651 0.79 PTGS1 (0.51) PTGS1PTGER2PTGDR2TBXA2RPTGDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 SRC 2996/4885SMN1; SMN2 2980/4885KDM4E 829/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 SRC 2996/4885SMN1; SMN2 2980/4885KDM4E 829/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.